TenoMab Biopharma submits registration for IPO on the science and technology innovation board, dedicated to innovative bio-pharmaceutical companies in blood product replacement therapy.

On May 22, Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. (referred to as "Tainuo Maibo") applied for a change in the IPO audit status of the Shanghai Stock Exchange Sci-Tech Innovation Board to "submit for registration." Huatai United Securities is its sponsor, intending to raise 1.5 billion yuan. According to the prospectus, the company was established in 2015 and is an innovative biopharmaceutical company dedicated to blood product replacement therapy for the global market. The company is guided by the principle of "creating clinical value", adhering to differentiated innovation and competitive strategies, and is committed to the development, manufacturing, commercialization, and potential substitution of globally specific blood products with fully human monoclonal antibodies to meet a wide range of clinical needs and benefit patients. For example, the company's core product, Staduta Monoclonal Antibody Injection (ie, "Recombinant Anti-tetanus toxin Human Whole Monoclonal Antibody TNM002," trade name: Xintitou, hereinafter referred to as "Staduta Monoclonal Antibody Injection" or "TNM002") was approved for listing in China in February 2025, being the globally first-in-class recombinant anti-tetanus toxin monoclonal antibody drug, recognized by China's CDE as a breakthrough therapy and included in the priority review process (also the first domestically innovative biopharmaceutical recognized as a breakthrough therapy in the anti-infection field), and included in the US FDA Fast Track qualification, holding global leadership in innovation in the field of tetanus prevention. Another core product, "Recombinant Anti-respiratory Syncytial Virus Human Whole Monoclonal Antibody TNM001" (hereinafter referred to as "TNM001") has been submitted for NDA for non-high-risk and high-risk infants and has been accepted, also included in the priority review process. After years of accumulation, the company has built a number of core technology platforms with independent intellectual property rights, such as the high-throughput fully human monoclonal antibody development comprehensive technology platform HitmAb, the high-efficiency antibody expression CHO-GS cell platform, the process development platform, the biological analysis platform, and other core technologies platforms, continuously fostering and improving innovative drug core technologies covering key drug research and industrialization links such as drug discovery, engineered cell strain construction, process and quality development, pharmacological research, toxicological research, pharmacokinetic research, clinical development, and GMP-compliant large-scale production. Among them, candidate antibody drugs incubated through the HitmAb platform have mature antibody structures selected through real human immune tolerance screening, are fully human monoclonal antibodies, with advantages such as strong specificity, high affinity, and safety, effectively reducing the adverse consequences of antibody immunogenicity, reducing clinical safety risks, and increasing drug success rates. Based on the above core technology platforms, as of the date of signing the prospectus, the company has developed multiple antibody molecules as candidate drugs covering areas such as infectious diseases and pain-related diseases. Among them, the globally first-in-class Staduta Monoclonal Antibody Injection has been approved for listing, TNM001 (anti-respiratory Syncytial Virus RSV monoclonal antibody) has been submitted for NDA for non-high-risk and high-risk infants and has been accepted, also included in the priority review process, 2 candidate drugs TNM009 (anti-nerve growth factor NGF monoclonal antibody) and TNM005 (anti-varicella-zoster virus VZV monoclonal antibody) have completed Phase I clinical trials, one candidate drug TNM006 (anti-human cytomegalovirus HCMV monoclonal antibody) has been approved for IND, and 3 candidate drugs are in the preclinical stage. Among these products, Staduta Monoclonal Antibody Injection and TNM005 are globally first-in-class or have the potential to be globally first-in-class. Financially, in 2024 and 2025, the company achieved operating income of RMB 15.0559 million and RMB 51.2249 million, respectively; during the same period, the company's net profit was approximately RMB -515 million and -601 million.